Plutux
Faeth Therapeutics, Inc. logo

Faeth Therapeutics, Inc.

FTH
$38.90
-0.26%
2026-09-04 09:37:53 EDT-$0.10
Healthcare
Biotechnology
NASDAQ
Active Trading

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. ...

Price Action

$38.90
-0.26%-$0.10
High—
Low—
52W High-4.9%
Rel. vol—
Interval
Range7m
Volume—SMA5SMA10
—

Company Overview

Faeth Therapeutics, Inc. (NASDAQ: FTH) is a U.S.-based, clinical-stage biotechnology company working to develop and advance novel treatments for patients with devastating forms of cancer. The company’s purpose is to improve patient lives by translating cancer biology into practical therapies, with an emphasis on multi-pathway targeting rather than single-agent approaches. ...Faeth Therapeutics, Inc. (NASDAQ: FTH) is a U.S.-based, clinical-stage biotechnology company working to develop and advance novel treatments for patients with devastating forms of cancer. The company’s purpose is to improve patient lives by translating cancer biology into practical therapies, with an emphasis on multi-pathway targeting rather than single-agent approaches. Business focus and strategy: Faeth’s core approach centers on identifying and disrupting key mechanisms cancer cells use to grow and survive. The provided materials highlight a lead program, PIKTOR, described as an investigational all-oral combination therapy designed to target the PI3K/AKT/mTOR pathway—an important signaling axis frequently implicated in oncogenesis and resistance. By concentrating on this pathway with a combination regimen, Faeth aims to improve clinical outcomes by simultaneously impacting interconnected nodes of tumor signaling. Products and pipeline orientation: As a clinical-stage biotech, Faeth’s “product” is best understood as its clinical development programs and regimen candidates advancing through study phases. PIKTOR represents the company’s most visible lead effort, and the overall portfolio is aligned to the company’s broader theme of targeting tumor metabolism and critical oncogenic pathways. Services and commercialization model: Faeth primarily operates as an R&D and development company rather than a provider of routine services or already-commercial products. Its work is typically structured around preclinical research, IND/enabling studies (where applicable), clinical trial design and execution, biomarker strategy, and progression of candidates based on emerging safety and efficacy data. Future commercialization—if successful—would likely involve partnered or direct commercialization of specific therapies, but near-term value is driven by trial progress and regulatory milestones. Costs, BOM, and financial profile (practical view): Like many early-to-mid stage biotechs, Faeth’s economics are generally dominated by R&D and clinical trial execution costs (personnel, trial operations, laboratory/assay work, regulatory activity, and manufacturing/quality systems). While the provided financial snapshot includes valuation and margin-related metrics, these figures are not reliable indicators of steady-state profitability because biotech companies often invest heavily before generating sustainable revenue. In this context, key “cost drivers” are clinical timelines and program risk: trial enrollment, operational burn rate, and the ability to secure sufficient capital. Key people: Anand Parikh serves as CEO and is identified as a founder/co-founder. The company was co-founded in 2019 alongside scientific leadership including Oliver Maddocks, PhD, and well-known cancer biologists such as Dr. Lewis Cantley, PhD—reflecting a foundation in oncology expertise. Wishes/near-term priorities: For companies like Faeth, the near-term objectives typically include generating compelling clinical data for lead programs (e.g., PIKTOR), demonstrating tolerability and meaningful efficacy, validating biomarkers, and maintaining financial runway to continue development through subsequent study stages.
Founded
2019
Employees
29
CEO
Anand Parikh
Full Name
Faeth Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
ROE
-192.76%
Market Cap
$1.01B
Current Ratio
19.69
WACC
5.44%
ROIC
-108.84%

Contact Information

https://www.faeththerapeutics.com
1405 Research Blvd, Rockville, MD 20850

Related stocksBiotechnology

Browse all US stocks →
About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026